BIOMARKERS OF TORCH TRIAL ON FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS

被引：0
|
作者：
Tsao, M. S. [1 ]
Gallo, C. [2 ]
Saieg, M. [1 ]
Santos, G. D. C. [1 ]
Gebbia, V. [3 ]
Perrone, F. [4 ]
Butts, C. [5 ]
Ciardiello, F. [2 ]
Feld, R. [1 ]
Gridelli, C. [6 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Naples 2, Naples, Italy
[3] Casa Cura Maddalena, Med Oncol, Palermo, Italy
[4] Natl Canc Inst, Clin Trials Unit, Naples, Italy
[5] Cross Canc Ctr, Edmonton, AB, Canada
[6] Azienda Osped SG Moscati, SG Moscati Hosp, Div Med Oncol, Avellino, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial
    Gridelli, Cesare
    Ciardiello, Fortunato
    Gallo, Ciro
    Feld, Ronald
    Butts, Charles
    Gebbia, Vittorio
    Maione, Paolo
    Morgillo, Floriana
    Genestreti, Giovenzio
    Favaretto, Adolfo
    Leighl, Natasha
    Wierzbicki, Rafal
    Cinieri, Saverio
    Alam, Yasmin
    Siena, Salvatore
    Tortora, Giampaolo
    Felletti, Raffaella
    Riccardi, Ferdinando
    Mancuso, Gianfranco
    Rossi, Antonio
    Cantile, Flavia
    Tsao, Ming-Sound
    Saieg, Mauro
    Santos, Gilda da Cunha
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Morabito, Alessandro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 3002 - 3011
  • [2] Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer
    Di Maio, Massimo
    Leighl, Natasha B.
    Gallo, Ciro
    Feld, Ronald
    Ciardiello, Fortunato
    Butts, Charles
    Maione, Paolo
    Gebbia, Vittorio
    Morgillo, Floriana
    Wierzbicki, Rafal
    Favaretto, Adolfo
    Alam, Yasmin
    Cinieri, Saverio
    Siena, Salvatore
    Bianco, Roberto
    Riccardi, Ferdinando
    Spatafora, Mario
    Ravaioli, Alberto
    Felletti, Raffaella
    Fregoni, Vittorio
    Genestreti, Giovenzio
    Rossi, Antonio
    Fregoni, Vittorio
    Genestreti, Giovenzio
    Rossi, Antonio
    Mancuso, Gianfranco
    Fasano, Morena
    Morabito, Alessandro
    Tsao, Ming Sound
    Signoriello, Simona
    Perrone, Francesco
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) : 1830 - 1844
  • [3] International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial
    Gridelli, C.
    Ciardiello, F.
    Feld, R.
    Butts, C. A.
    Gebbia, V.
    Genestreti, G.
    Favaretto, A. G.
    Wierzbicki, R.
    Gallo, C.
    Perrone, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer
    Cao, Wa
    Li, Ai-Wu
    Ren, Sheng-Xiang
    Chen, Xiao-Xia
    Li, Wei
    Gao, Guang-Hui
    He, Ya-Yi
    Zhou, Cai-Cun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) : 6799 - 6804
  • [5] An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: Treatment rationale and protocol dynamics of the TORCH trial
    Gridelli, Cesare
    Bufts, Charles
    Ciardiello, Fortunato
    Feld, Ronald
    Gallo, Ciro
    Perrone, Francesco
    CLINICAL LUNG CANCER, 2008, 9 (04) : 235 - 238
  • [6] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    LUNG CANCER, 2010, 67 (03) : 348 - 354
  • [7] Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer
    Cucevic, B
    Samarzija, M
    Baricevic, D
    Jakopovic, M
    Redzepi, G
    Samija, M
    COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 583 - 588
  • [8] Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
    Kim, Lucia
    Saieg, Mauro
    Di Maio, Massimo
    Gallo, Ciro
    Butts, Charles
    Ciardiello, Fortunato
    Feld, Ronald
    Cheng, Dengxiao
    Gebbia, Vittorio
    Burgio, Marco Angelo
    Alam, Yasmin
    Signoriello, Simona
    Rossi, Antonio
    Leighl, Natasha
    Maione, Paolo
    Morabito, Alessandro
    Liu, Geoffrey
    Tsao, Ming-Sound
    Perrone, Francesco
    Gridelli, Cesare
    ONCOTARGET, 2017, 8 (34) : 57528 - 57536
  • [9] Second-line chemotherapy for non-small cell lung cancer
    De Marinis, F.
    De Santis, S.
    De Petris, L.
    ANNALS OF ONCOLOGY, 2006, 17 : V68 - V71
  • [10] Second-line chemotherapy for non-small cell lung cancer
    Ruckdeschel, JC
    CHEST, 2006, 129 (04) : 840 - 842
12345